Novo Nordisk said Thursday that the rampant growth of the U.S.’ compounded drug industry was hurting Wegovy sales, and warned ...

The "Diabetes Monitoring, Treatment and Drug Delivery Market Size, Share & Trends Analysis | United States | 2025-2031 | MedSuite | Includes: Insulin & GLP-1, Continuous Glucose Monitoring and 7 more" ...

Just about a year after launching a direct-to-consumer online platform to sell treatments for diabetes and obesity, Eli Lilly ...

Eli Lilly (NYSE: LLY) has emerged as one of the hottest stocks in the GLP-1 realm -- underscored by its combination of ...

Eli Lilly & Co. is adding Alzheimer’s disease resources to the online platform it launched a year ago to sell obesity, ...

Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...

Cooper Flagg #2 of the Duke Blue Devils defends Jason Asemota #5 of the Baylor Bears during the second round of the 2025 NCAA ...

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

Eli Lilly and Novo Nordisk have scored big wins from the FDA in recent months, as the agency cracks down on copycat versions ...

Today, the Obesity Action Coalition (OAC) and The Obesity Society (TOS) sent a letter to the U.S. Food & Drug Administration (FDA), along with more than 20 leading organizations and providers across ...

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...

Eli Lilly (LLY) launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk (NVO) for a ...